Serum proteomic profiling of major depressive disorder

Translational Psychiatry

Volumn 5, Issue 7, 2015, Pages

  Bot, M ^a   Chan, M K ^b   Jansen, R ^a   Lamers, F ^a   Vogelzangs, N ^a   Steiner, J ^c   Leweke, F M ^d   Rothermundt, M ^e,f   Cooper, J ^b   Bahn, S ^b,g   Penninx, B W J H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f Ventilatory Support and Sleep   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MACROPHAGE MIGRATION INHIBITION FACTOR; PLASMA PROTEIN; POLYPEPTIDE; TENASCIN; VON WILLEBRAND FACTOR;

ANXIETY; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; COMORBIDITY; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NETHERLANDS; PROTEIN METABOLISM; PROTEOMICS; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; ADULT; BLOOD; CASE CONTROL STUDY; FEMALE; MALE; METABOLISM; PROCEDURES;

ADULT; BIOMARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; PROTEOMICS;

EID: 84988905789     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.88     Document Type: Article

References (48)

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-3105.
2. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
3. Belmaker RH, Agam G. Mechanisms of disease: Major depressive disorder. N Engl J Med 2008; 358: 55-68.
4. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: Review and meta-analysis. Am J Psychiatry 2000; 157: 1552-1562.
5. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 2013; 18: 497-511.
6. Filiou MD, Turck CW, Martins-de-Souza D. Quantitative proteomics for investigating psychiatric disorders. Proteomics Clin Appl 2011; 5: 38-49.
7. Herberth M, Koethe D, Levin Y, Schwarz E, Krzyszton ND, Schoeffmann S et al. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics 2011; 11: 94-105.
8. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2012; 17: 494-502.
9. Ditzen C, Tang N, Jastorff AM, Teplytska L, Yassouridis A, Maccarrone G et al. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology 2012; 37: 1013-1025.
10. Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry 2012; 2: E87.
11. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010; 5: E9166.
12. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH et al. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol 2008; 18: 230-233.
13. Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X et al. Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry 2012; 2: E65.
14. Zheng P, Gao HC, Li Q, Shao WH, Zhang ML, Cheng K et al. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J Proteome Res 2012; 11: 1741-1748.
15. Zheng P, Wang Y, Chen L, Yang D, Meng H, Zhou D et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol Cell Proteomics 2013; 12: 207-214.
16. Lu S, Peng H, Wang L, Vasish S, Zhang Y, Gao W et al. Elevated specific peripheral cytokines found in major depressive disorder patients with childhood trauma exposure: A cytokine antibody array analysis. Compr Psychiatry 2013; 54: 953-961.
17. Xu HB, Fang L, Hu ZC, Chen YC, Chen JJ, Li FF et al. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res 2012; 200: 1054-1057.
18. Xu HB, Zhang RF, Luo D, Zhou Y, Wang Y, Fang L et al. Comparative proteomic analysis of plasma from major depressive patients: Identification of proteins associated with lipid metabolism and immunoregulation. Int J Neuropsychopharmacol 2012; 15: 1413-1425.
19. Penninx BWJH, Beekman ATF, Smit JH, Zitman FG, Nolen WA, Spinhoven P et al. The Netherlands Study of Depression and Anxiety (NESDA): Rationale, objectives and methods. Int J Methods Psychiatr Res 2008; 17: 121-140.
20. Wittchen HU. Reliability and validity studies of the who composite international diagnostic interview (Cidi) - A critical-review. J Psychiatr Res 1994; 28: 57-84.
21. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med 1996; 26: 477-486.
22. World Health Organization. Collaboration Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification System. World Health Organization: Oslo, Norway, 2007.
23. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381-1395.
24. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127.
25. Lamers F, van Oppen P, Comijs HC, Smit JH, Spinhoven P, van Balkom AJ et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: The Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 2011; 72: 341-348.
26. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. URLhttp: //www.R-project.org/ (computer program) 2013.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc 1995; 57: 289-300.
28. Prasad TS, Kandasamy K, Pandey A. Human protein reference database and human proteinpedia as discovery tools for systems biology. Methods Mol Biol 2009; 577: 67-79.
29. Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: Modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 2013; 41: D377-D386.
30. Kundu S, Aulchenko YS, van Duijn CM, Janssens AC. PredictABEL: An R package for the assessment of risk prediction models. Eur J Epidemiol 2011; 26: 261-264.
31. Redei EE, Andrus BM, Kwasny MJ, Seok J, Cai X, Ho J et al. Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy. Transl Psychiatry 2014; 4: E442.
32. Bloom J, Al-Abed Y. MIF: Mood improving/inhibiting factor? J Neuroinflammation 2014; 11: 11.
33. Maes M, Bosmans E, De JR, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853-858.
34. Milaneschi Y, Corsi AM, Penninx BW, Bandinelli S, Guralnik JM, Ferrucci L et al. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: The InCHIANTI study. Biol Psychiatry 2009; 65: 973-978.
35. McCaffery JM, Duan QL, Frasure-Smith N, Barhdadi A, Lespérance F, Théroux P et al. Genetic predictors of depressive symptoms in cardiac patients. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 381-388.
36. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88: 3989-3992.
37. Powell TR, McGuffin P, D'Souza UM, Cohen-Woods S, Hosang GM, Martin C et al. Putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients. PLoS One 2014; 9: E91076.
38. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001; 69: 986-994.
39. Kosaki A, Hasegawa T, Kimura T, Iida K, Hitomi J, Matsubara H et al. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5423-5428.
40. Golledge J, Clancy P, Maguire J, Lincz L, Koblar S. The role of tenascin C in cardiovascular disease. Cardiovasc Res 2011; 92: 19-28.
41. Wang Y, Chen J, Chen L, Zheng P, Xu HB, Lu J et al. Urinary peptidomics identifies potential biomarkers for major depressive disorder. Psychiatry Res 2014; 217: 25-33.
42. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: A pilot and replication study. Mol Psychiatry 2013; 18: 332-339.
43. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med 2009; 71: 171-186.
44. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A metaanalysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
45. Vogelzangs N, Duivis HE, Beekman AT, Kluft C, Neuteboom J, Hoogendijk W et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry 2012; 2: E79.
46. van Beveren NJ, Schwarz E, Noll R, Guest PC, Meijer C, de Haan L et al. Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. Transl Psychiatry 2014; 4: E430.
47. Hayes LN, Severance EG, Leek JT, Gressitt KL, Rohleder C, Coughlin JM et al. Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr Bull 2014; 40: 963-972.
48. Haenisch F, Alsaif M, Guest PC, Rahmoune H, Dickerson F, Yolken R et al. Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3beta signaling in bipolar patients. J Affect Disord 2014; 156: 139-143.